PL3570940T3 - Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x - Google Patents
Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu xInfo
- Publication number
- PL3570940T3 PL3570940T3 PL18741607.8T PL18741607T PL3570940T3 PL 3570940 T3 PL3570940 T3 PL 3570940T3 PL 18741607 T PL18741607 T PL 18741607T PL 3570940 T3 PL3570940 T3 PL 3570940T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- fragile
- syndrome
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448595P | 2017-01-20 | 2017-01-20 | |
| PCT/US2018/014169 WO2018136600A1 (en) | 2017-01-20 | 2018-01-18 | Use of pridopidine for the treatment of fragile x syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3570940T3 true PL3570940T3 (pl) | 2024-06-17 |
Family
ID=62908348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18741607.8T PL3570940T3 (pl) | 2017-01-20 | 2018-01-18 | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11234973B2 (https=) |
| EP (1) | EP3570940B1 (https=) |
| JP (1) | JP7114604B2 (https=) |
| CN (1) | CN110505902B (https=) |
| AU (1) | AU2018210145B2 (https=) |
| BR (1) | BR112019015000A2 (https=) |
| CA (1) | CA3050700C (https=) |
| DK (1) | DK3570940T3 (https=) |
| ES (1) | ES2972205T3 (https=) |
| HU (1) | HUE068300T2 (https=) |
| IL (1) | IL268125B2 (https=) |
| PL (1) | PL3570940T3 (https=) |
| WO (1) | WO2018136600A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| KR102528677B1 (ko) * | 2020-01-08 | 2023-05-04 | 주식회사 뉴로벤티 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6472736A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Mri apparatus |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CN101068782A (zh) | 2004-10-13 | 2007-11-07 | 神经研究瑞典公司 | 合成4－(3－磺酰基苯基)－哌啶类的方法 |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| AU2012209466C1 (en) | 2011-01-27 | 2016-06-23 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| EP2900226A4 (en) * | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| JP7436524B2 (ja) | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
-
2018
- 2018-01-18 CA CA3050700A patent/CA3050700C/en active Active
- 2018-01-18 EP EP18741607.8A patent/EP3570940B1/en active Active
- 2018-01-18 WO PCT/US2018/014169 patent/WO2018136600A1/en not_active Ceased
- 2018-01-18 PL PL18741607.8T patent/PL3570940T3/pl unknown
- 2018-01-18 ES ES18741607T patent/ES2972205T3/es active Active
- 2018-01-18 AU AU2018210145A patent/AU2018210145B2/en active Active
- 2018-01-18 JP JP2019539958A patent/JP7114604B2/ja active Active
- 2018-01-18 HU HUE18741607A patent/HUE068300T2/hu unknown
- 2018-01-18 BR BR112019015000-5A patent/BR112019015000A2/pt not_active Application Discontinuation
- 2018-01-18 IL IL268125A patent/IL268125B2/en unknown
- 2018-01-18 DK DK18741607.8T patent/DK3570940T3/da active
- 2018-01-18 CN CN201880007913.2A patent/CN110505902B/zh active Active
-
2019
- 2019-07-17 US US16/514,167 patent/US11234973B2/en active Active
-
2022
- 2022-01-31 US US17/588,403 patent/US12551474B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11234973B2 (en) | 2022-02-01 |
| US20220202798A1 (en) | 2022-06-30 |
| CA3050700C (en) | 2023-10-03 |
| AU2018210145A1 (en) | 2019-08-29 |
| CN110505902A (zh) | 2019-11-26 |
| DK3570940T3 (da) | 2024-02-19 |
| IL268125A (en) | 2019-09-26 |
| HUE068300T2 (hu) | 2024-12-28 |
| AU2018210145B2 (en) | 2023-06-29 |
| EP3570940A4 (en) | 2020-10-28 |
| BR112019015000A2 (pt) | 2020-04-07 |
| JP7114604B2 (ja) | 2022-08-08 |
| CN110505902B (zh) | 2022-11-11 |
| US12551474B2 (en) | 2026-02-17 |
| CA3050700A1 (en) | 2018-07-26 |
| IL268125B (en) | 2022-12-01 |
| ES2972205T3 (es) | 2024-06-11 |
| IL268125B2 (en) | 2023-04-01 |
| WO2018136600A1 (en) | 2018-07-26 |
| JP2020514313A (ja) | 2020-05-21 |
| US20190336488A1 (en) | 2019-11-07 |
| EP3570940A1 (en) | 2019-11-27 |
| EP3570940B1 (en) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273495A (en) | Treatment of fragile X syndrome with cannabidiol | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| HUE068300T2 (hu) | Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra | |
| IL258964A (en) | Thin and flexible absorbent items | |
| IL250016A0 (en) | Antisense oligonucleotides for the treatment of type 2 syndrome | |
| IL258962A (en) | Thin and flexible absorbent items | |
| GB2574762B (en) | Absorbent article | |
| GB201621480D0 (en) | Use of cannabinoids in the treatment of angelman syndrome | |
| IL258963A (en) | Thin and flexible absorbent items | |
| GB2574984B (en) | Thong-style absorbent article | |
| SG11202004898VA (en) | Underpants-shaped absorbent article | |
| GB2581054B (en) | Absorbent article | |
| GB2581058B (en) | Absorbent article | |
| SG11202000921XA (en) | Absorbent article | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3397270T3 (pl) | Kompozycje do zastosowania w leczeniu zespołu huntera | |
| ZA202003100B (en) | Absorbent article component | |
| GB202017373D0 (en) | Absorbent article | |
| PL3716927T3 (pl) | Wyrób chłonny | |
| PL3691592T3 (pl) | Wyrób chłonny | |
| GB2581084B (en) | Absorbent article | |
| SG11202000922VA (en) | Absorbent article | |
| CA186506S (en) | Absorbent article | |
| CA186507S (en) | Absorbent article | |
| CA186508S (en) | Absorbent article |